#KiteNews: Today, we announced results from four analyses that continue to demonstrate the durability of response of Kite’s CAR T-cell therapy in patients with relapsed/refractory mantle cell lymphoma (MCL) and relapsed/refractory B-cell precursor acute lymphoblastic leukemia during #ASH24. The results demonstrate prolonged overall survival after five years follow-up in R/R MCL in some patients. Read more: https://bit.ly/3DiPct1
Kite Pharma’s Post
More Relevant Posts
-
Pancreatic Lymphoma: CT Findings https://lnkd.in/gRhi8YD4
-
-
Accelerate the clinical development to benefit CLL/SLL patients.
Excited to announce the IND approval to conduct the clinical trial of BCL2 inhibitor ICP-248 in combination with BTK inhibitor orelabrutinib as first-line therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in China. https://lnkd.in/ewtphwAE
-
-
Scientific advances in #CLL / #SLL in the last decade have propelled the management landscape From a disease treatment dominated by chemimmunotherapy to a shy role of targeted therapies (#BTKi), which later on evolved pinning the last nail in the coffin of chemotherapy-based regimens, and now redefining CLL/SLL treatment by coming in different flavours (indefinite vs fixed-duration regimens #BCL2inh) Now we are witnessing a "one-off" regimen with the advent of cellular therapies #CART in later lines Some pending points: 1) Provided the relatively indolent course of CLL/SLL, will it be justifiable to have CART in such a setting? or better spare it for patients with Richter's transformation especially of the LBCL subtype 2) the reported ORRs herein are not matching those of cellular therapies in other haematological malignancies, will there be a role for combinations? #patients_first #science_forward
BREAKING: The FDA has granted accelerated approval to lisocabtagene maraleucel (Breyanzi) for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who have previously received at least 2 prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor. https://lnkd.in/gb6uJy6w
-
-
Lisocabtagene maraleucel (liso-cel) has just become the first CAR-T therapy approved by the FDA for relapsed/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). This is an important approval for CLL patients who have undergone multiple courses of treatment and finally provides access to a cellular CAR-T therapy outside of a clinical trial. Read CLL Society's article on this news at: https://bit.ly/3wYbHR7
-
-
Managing follicular lymphoma: How bispecific antibodies impact every line of therapy 👉 https://lnkd.in/eXqCe3ip Listen in as two experts examine the latest data in novel CD20/CD3 bispecific antibodies for patients with R/R FL #Hematology #Oncology #MedEd #GetYourAnswersinCME
-
Metabolic Regulation of Lymphoma Development: #AACRFellows Tak W. Mak will address this topic in a keynote lecture at the Fourth AACR International Meeting on Advances in Malignant Lymphoma (June 19-22, Philadelphia). Learn more: https://bit.ly/3IOXuIW #AACRlymph24
-
-
💫 #ONCOnews 💫 🌟 EU’s CHMP Recommends Odronextamab Approval in Follicular Lymphoma, DLBCL 👉 Recommendation based on Phase 1 and pivotal Phase 2 trials showing strong and lasting response rates in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma. 🔗 https://buff.ly/45VPCjy #OncEd #OncoAlert
-
-
CAR T Therapy: A Path of Hope and Healing For over 7 years, CAR T therapy has offered renewed hope to thousands of patients with multiple myeloma, large B lymphoma, and other forms of lymphoma and leukemia. PIXACORE is proud to partner with The Leukemia & Lymphoma Society (LLS) to present an inspiring new docuseries on the power of CAR T therapy. This series raises awareness of this transformative treatment, showcasing its profound impact on patient outcomes, access to care, and community engagement. We are thrilled to announce that the full docuseries, "CAR T Therapy: A Path of Hope and Healing," is now available! Thank you to LLS, Dr. Carl June, and our sponsors Kite, Bristol Myers Squibb, and Johnson & Johnson & LEGEND BIOTECH for making this vision a reality. Watch the full docuseries here: https://lnkd.in/ebMT29dU #CARTCellTherapy #celltherapy #Leukemia #Lymphoma #LLS #PIXACORE #ASH2024 #Myeloma #DLBCL
-
Corporate Affairs Leader | Corporate Reputation | Product Communications | Colleague Engagement | Patient Advocacy | Public Affairs
September is #BloodCancerAwarenessMonth, and we at BeiGene are deeply committed to shining a light on the more than 1.3 million people diagnosed globally with leukemia, multiple myeloma, non-Hodgkin lymphoma, and Hodgkin lymphoma each year. Together, we're making a difference, one step at a time. Learn more about our focus on hematologic malignancies: https://bit.ly/4c3Czh9
-
